Clinical Trial Update: Trial to Evaluate the Safety and Immunogenicity of Priming Regimens of 426c.Mod.Core-C4b and Optional Boost Regimen With HIV Trimer BG505 SOSIP.GT1.1 gp140, Both Adjuvanted With 3M-052-AF + Alum in Healthy, Adult Participants Without HIV [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating safety and immunogenicity of priming regimens for an HIV vaccine using 426c.Mod.Core-C4b and BG505 SOSIP.GT1.1 gp140, with 3M-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• 3M-052 AF (TLR7/8 agonist adjuvant)
• 426c.Mod.Core-C4b
• Alum (aluminum-based adjuvant)
• BG505 SOSIP.GT1.1 gp140

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV-1-infection | Phase 1 | Status: ACTIVE_NOT_RECRUITING